Clinical Trial: CBD Administration Associated with Greater Likelihood of Cannabis Abstinence Among Those Seeking to Quit

London, United Kingdom: The administration of high doses of cannabidiol is associated with increased cannabis abstinence among marijuana consumers seeking to quit, according to placebo-controlled clinical data published in the journal Lancet Psychiatry,

A team of researchers from the University College of London assessed the use of CBD versus placebo over a 12-week period in a group of 82 participants diagnosed with problematic cannabis use. All of the study’s subjects had expressed a desire to quit cannabis, but had previously been unable to successfully do so.

Authors reported that daily doses of 400 mgs of CBD decreased the number of cannabis cigarettes that subjects smoked per week. Doses of 800 mgs of CBD were associated with less significant changes in outcomes compared to placebo, while doses of 200 mgs of CBD were not shown to be effective.

They concluded, “In the first randomized clinical trial of cannabidiol for cannabis use disorder, cannabidiol [doses of] 400 mg and 800 mg were safe and more efficacious than placebo at reducing cannabis use.”

Prior clinical trials have reported that CBD administration is associated with reduced cravings for both heroin and tobacco. A literature review published in the journal Substance Abuse: Research and Treatment previously concluded, “CBD seems to have direct effects on addictive behaviors.”

Full text of the study, “Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomized, adaptive Bayesian trial,” appears in Lancet Psychiatry.